Clinical trials AI is a domain where hype and reality have had particularly divergent trajectories. The headlines promise trials that run themselves; the reality is AI accelerating specific bottlenecks while the overall trial structure remains firmly human and regulated. This post is where AI actually ships in pharmaceutical clinical development and the FDA guidance shaping 2026 deployments.
Protocol design
Eligibility criteria NLP. Extracting structured criteria from existing protocols, testing them against EHR databases to estimate recruitable population. Identifies overly restrictive criteria before protocol finalization.
Sample size simulation. Given assumed effect sizes and variance, Monte Carlo simulations estimate power across scenarios. Not new; AI makes it more accessible to trial teams without heavy biostatistics support.
Comparator arm design. AI flags similar recent trials, their design choices, their results. Informs comparator selection without replacing human judgment.
Recruitment — the biggest win
Patient matching from EHR. Protocol eligibility criteria matched against real patient records. AI flags potentially-eligible patients for clinical team review. Hit rates 3-10x manual screening.
Site selection. Historical site data (previous trial enrollment rates, patient demographics, investigator track records) matched to protocol needs. AI suggests sites; human team validates.
Consent form simplification. Informed consent forms run 20-50 pages; patients don't read them well. AI generates plain-language summaries; ethics committee reviews; patients see both detailed and simplified versions.
Recruitment is where trials typically slip. AI-driven recruitment genuinely accelerates enrollment timelines by 20-40% in trials that have deployed it well.
Trial conduct and analysis
Adverse event detection. AI monitors incoming data for safety signals. Flags anomalies for human pharmacovigilance review. Faster detection of safety issues.
Data query resolution. Protocol deviations, missing data, inconsistencies — AI triages; clinical data managers resolve. Cuts manual query workload 40-60%.
Medical writing drafts. Clinical Study Reports (CSRs) are 300+ pages of highly-structured regulatory writing. AI drafts standard sections; medical writers review and refine. Cycle time from lock to CSR drops 30-50%.
FDA guidance (2024-2025)
Risk-based framework. The FDA has published guidance on AI/ML in drug development. Higher-risk applications (primary efficacy analysis) face stricter validation; lower-risk applications (operational efficiency) face lighter review.
Validation expected. Before AI is used in regulatory submissions, validation against predefined criteria. Documentation substantial.
Data integrity. 21 CFR Part 11 compliance applies to AI outputs that form part of submissions. Audit trails, electronic signatures, version control.
Pharmacovigilance. AI supplementing safety signal detection is accepted; replacing required pharmacovigilance procedures is not.
What stays human
Protocol approval. IRBs, ethics committees, regulatory authorities all review protocols. AI doesn't decide what studies run.
Primary efficacy analysis. The statistical analysis that determines trial success remains human-designed, human-executed, subject to pre-specified analysis plans.
Safety decisions. Stopping trials for safety, dose reductions, protocol amendments — all human decisions informed by data.
Patient consent. AI cannot consent patients. Clinicians, nurses, patients themselves remain the principals.
Rollout pattern
Early wins in operational efficiency: recruitment, document processing, adverse event triage. Lower regulatory risk; clearer ROI.
Later expansion to analytical uses with appropriate validation. Build up evidence of validation quality before high-stakes applications.
CROs (contract research organizations) ahead of sponsors on AI deployment typically. Vendor ecosystem mature; major CROs all have AI platforms.
Economic impact
Trial cost typically $50-300M per pivotal study. AI deployment that cuts timeline by months translates to material savings and faster time to market.
Not transformative; incremental. A 6-month faster trial is significant. A 12-year drug development cycle isn't going to shrink to 5 years through AI alone.